Terms: = Ovarian cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Treatment
21 results:
1. The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Li X; Gao X; Yuan J; Wang F; Xu X; Wang C; Liu H; Guan W; Zhang J; Xu G
Front Endocrinol (Lausanne); 2022; 13():950345. PubMed ID: 36120434
[TBL] [Abstract] [Full Text] [Related]
2. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
3. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
Lutgendorf SK; Penedo F; Goodheart MJ; Dahmoush L; Arevalo JMG; Thaker PH; Slavich GM; Sood AK; Cole SW
Cancer; 2020 Oct; 126(19):4407-4413. PubMed ID: 32691853
[TBL] [Abstract] [Full Text] [Related]
4. Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-β pathway.
Wen H; Qian M; He J; Li M; Yu Q; Leng Z
PLoS One; 2020; 15(3):e0230230. PubMed ID: 32214328
[TBL] [Abstract] [Full Text] [Related]
5. A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer.
Song J; Le T; Hopkins L; Fung-Kee-Fung M; Lupe K; Gaudet M; E C; Samant R
Int J Gynecol Cancer; 2020 Feb; 30(2):160-166. PubMed ID: 31871112
[TBL] [Abstract] [Full Text] [Related]
6. Activin A promotes ovarian cancer cell migration by suppressing E-cadherin expression.
Yi Y; Cheng JC; Klausen C; Leung PCK
Exp Cell Res; 2019 Sep; 382(2):111471. PubMed ID: 31229504
[TBL] [Abstract] [Full Text] [Related]
7. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract] [Full Text] [Related]
8. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract] [Full Text] [Related]
9. Upregulation of MiR-205 transcriptionally suppresses smad4 and PTEN and contributes to human ovarian cancer progression.
Li J; Hu K; Gong G; Zhu D; Wang Y; Liu H; Wu X
Sci Rep; 2017 Feb; 7():41330. PubMed ID: 28145479
[TBL] [Abstract] [Full Text] [Related]
10. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract] [Full Text] [Related]
11. Growth differentiation factor 8 induces SKOV3 ovarian cancer cell migration and E-cadherin down-regulation.
Zhao J; Klausen C; Xiong S; Cheng JC; Chang HM; Leung PC
Cell Signal; 2016 Nov; 28(11):1615-22. PubMed ID: 27481097
[TBL] [Abstract] [Full Text] [Related]
12. [Gynecologic cancers in a hospital: a retrospective analysis of admission data over ten years].
Chen MQ; Gong MQ; Gao HC; Gao XM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 46(2):326-30. PubMed ID: 25924453
[TBL] [Abstract] [Full Text] [Related]
13. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract] [Full Text] [Related]
14. Genetic testing by cancer site: stomach.
Chun N; Ford JM
Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
[TBL] [Abstract] [Full Text] [Related]
15. Aberrant TGFβ/smad4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.
Yeh KT; Chen TH; Yang HW; Chou JL; Chen LY; Yeh CM; Chen YH; Lin RI; Su HY; Chen GC; Deatherage DE; Huang YW; Yan PS; Lin HJ; Nephew KP; Huang TH; Lai HC; Chan MW
Epigenetics; 2011 Jun; 6(6):727-39. PubMed ID: 21540640
[TBL] [Abstract] [Full Text] [Related]
16. Promoter hypermethylation of FBXO32, a novel TGF-beta/smad4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
[TBL] [Abstract] [Full Text] [Related]
17. Immunohistochemical localization of inhibin and activin subunits, activin receptors and Smads in ovarian endometriosis.
Mabuchi Y; Yamoto M; Minami S; Umesaki N
Int J Mol Med; 2010 Jan; 25(1):17-23. PubMed ID: 19956897
[TBL] [Abstract] [Full Text] [Related]
18. Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells.
Shepherd TG; Thériault BL; Nachtigal MW
Gene; 2008 May; 414(1-2):95-105. PubMed ID: 18372118
[TBL] [Abstract] [Full Text] [Related]
19. [Hereditary colorectal cancer].
Park JG; Kim IJ
Korean J Gastroenterol; 2005 Feb; 45(2):78-87. PubMed ID: 15725711
[TBL] [Abstract] [Full Text] [Related]
20. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Baldwin RL; Tran H; Karlan BY
Cancer Res; 2003 Mar; 63(6):1413-9. PubMed ID: 12649207
[TBL] [Abstract] [Full Text] [Related]
[Next]
